Skip to main content
. 2014 Oct 13;19(6):933–939. doi: 10.1007/s00776-014-0633-0

Fig. 2.

Fig. 2

The improved VAS scores in the two groups are presented as means ± SDs. Except for the patients with initial VAS scores of 0.15 or less, the improved VAS scores were significantly larger in the Theracurmin group than in the placebo group at 8 weeks (P = 0.023)